PDCD1 and neoplasm: A strong immune-memory effect (ca. 100% tumour rejection rate) is observed after GL261 tumour ablation with anti-PD-1 monotherapy, whereas a weaker anti-tumour immune memory capability (50% tumour rejection rate) was found in mice cured by anti-PD-1/TMZ combined therapy.